Drug Interaction Report

Consumer information for this interaction is not currently available.

ADJUST DOSE: Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of crinecerfont, which is primarily metabolized by the isoenzyme. Concomitant use with rifampin, a potent CYP450 3A4 inducer, decreased crinecerfont peak plasma concentration (Cmax) and systemic exposure (AUC) by 23% and 62%, respectively. Reduced efficacy of cinecerfont may occur.

MANAGEMENT : When coadministered with potent CYP450 3A4 inducers, the crinecerfont morning and evening doses should be increased.
In adults, increase the crinecerfont dose to 200 mg twice daily with a meal in the morning and evening.

In pediatric patients 4 years of age and older, increase the crinecerfont dose based on weight:
-Patients weighing 10 kg to less than 20 kg: 50 mg twice daily with a meal in the morning and evening
-Patients weighing 20 kg to less than 55 kg: 100 mg twice daily with a meal in the morning and evening
-Patients weighing 55 kg or more: 200 mg twice daily with a meal in the morning and evening

You should preferably avoid the regular consumption of grapefruits and grapefruit juice while taking carBAMazepine. This can cause carBAMazepine levels to increase. You should report signs of carBAMazepine side effects such as nausea, visual disturbances, dizziness, or muscle weakness to your doctor. You should avoid or limit the use of alcohol while being treated with carBAMazepine. Alcohol can increase the nervous system side effects of carBAMazepine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. Talk to your doctor or pharmacist if you have any questions or concerns.

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of crinecerfont. Administration of crinecerfont capsules and oral solution with a high-fat meal (800 to 1000 calories, 50% fat), increased crinecerfont peak plasma concentration (Cmax) by 4.9-fold and 8.6-fold, respectively, and systemic exposure (AUC) by 3.3-fold and 8.3-fold, respectively, compared to administration under fasting conditions.

MANAGEMENT: Crinecerfont should be administered twice daily with a meal in the morning and evening without regard to fat or calorie content.